effect
cyclosporin
csa
neuropatholog
lesion
induc
chronic
viral
infect
test
experiment
model
mous
hepat
viru
infect
daili
inject
csa
mgkg
inhibit
express
ependym
mening
hydrocephalu
vascul
effect
preserv
even
csa
treatment
initi
day
viru
infect
lost
csa
treatment
given
later
shorter
period
time
viral
titer
brain
chronic
infect
mice
affect
csa
treatment
first
week
follow
infect
csa
treatment
increas
percentag
acut
death
vs
viral
titer
brain
liver
infect
mice
model
time
csa
treatment
appear
critic
balanc
benefici
effect
cn
lesion
risk
increas
acut
mortal
cyclosporin
csa
potent
immunomodul
agent
whose
benefici
effect
graft
toler
demonstr
experiment
anim
tran
plant
patient
csa
appear
also
activ
sever
autoimmun
diseas
uveiti
type
diabet
wherea
consequ
csa
treatment
wral
diseas
postvir
immun
respons
less
extens
studi
johnson
view
potenti
therapeut
import
csa
human
postinfecti
chronic
viral
enceph
seri
experi
design
apprais
therapeut
effect
csa
central
nervou
system
cn
lesion
induc
experiment
chronic
viral
infect
intraperiton
inject
mous
hepat
viru
type
member
coronaviru
group
adult
ch
mice
result
either
earli
death
due
acut
hepat
dc
chronic
oiseas
oemoiog
manifest
viru
pertencc
surviv
anim
virelizi
tardieu
chronic
neurolog
diseas
result
mening
ependym
arid
enceph
begin
week
elsevi
scienc
faolish
bv
biomed
divis
infect
follow
perman
commun
hydrocephalu
later
week
postinfect
chronic
thrombot
vascul
develop
affect
mening
parenchym
vessel
brain
stem
level
tardieu
model
allow
studi
effect
csa
acut
phase
depend
intens
viral
replic
chronic
intracn
lesion
induc
chronic
viral
infect
inbr
mous
strain
orl
purchas
centr
de
et
dlevag
danimaux
de
iaboratoir
cnr
odansla
sourc
franc
origin
obtain
jm
dupuy
bic
franc
plaqu
purifi
grown
cell
previous
describ
tardieu
tenweekold
anim
infect
intraperiton
ip
pfu
viral
titrat
anim
anesthet
ether
perfus
phosphatebuff
salin
pb
rain
left
ventricl
liver
brain
remov
frozen
c
ml
pb
solut
thaw
sonicar
assay
presenc
viru
plaqu
titrat
cell
sturman
neuropathologicai
studi
anim
perfus
paraformaldehyd
ww
use
procedur
pb
perfus
organ
remov
process
previous
describ
tardieu
brain
two
independ
examin
evalu
intens
mening
hydrocephalu
vascul
notat
coron
serial
ttm
thick
section
brain
stem
later
hemispher
level
blood
sampl
obtain
anesthet
anim
retroorbit
punctur
direct
cardiac
punctur
time
death
antibodi
titer
either
enzymelink
immunoabsorb
assay
elisa
neutral
neutral
assay
pfu
incub
min
serial
dilut
sera
obtain
infect
noninfect
mice
subsequ
titer
plaqu
assay
highest
dilut
serum
reduc
viral
titer
use
neutral
titer
interferon
assay
vesicular
stomat
viru
vsv
plaqu
reduct
assay
cell
sampl
serum
individu
test
absenc
infect
check
sampl
cyclosporin
obtain
sandoz
laboratori
dilut
mgml
oliv
oil
inject
subcutan
everi
day
mg
per
anim
ie
mgkg
cyclosporin
level
determin
highperform
liquid
chromatographi
hplc
whole
blood
obtain
retroorbit
punctur
perform
next
csa
inject
briefli
titrat
techniqu
involv
prepar
blood
sampl
liquidliquid
extract
follow
isocrat
reversedphas
liquid
chromatographi
ultraviolet
uv
detect
nm
quantif
perform
rel
cyelosporin
intern
standard
method
permit
reliabl
measur
standard
deviat
ngml
determin
kindli
perform
l
vernillet
jf
le
bigot
laboratoir
sandoz
franc
anim
infect
csa
treatment
proceed
follow
group
continu
daili
subcutan
inject
oliv
oil
dilut
vehicl
csa
group
b
continu
daili
csa
treatment
start
time
infect
group
c
continu
daili
csa
treatment
start
either
day
infect
group
discontinu
treatment
daili
csa
treatment
given
day
start
day
postinfect
pi
group
sever
paramet
record
anim
death
viral
titer
liver
brain
day
first
week
pi
determin
viral
replic
week
pi
determin
viral
persist
antibodi
titer
everi
week
week
neuropatholog
lesion
determin
week
pi
control
group
mice
kept
noninfect
inject
daili
csa
oliv
oil
statist
analysi
mous
surviv
statist
analysi
mous
surviv
perform
log
rank
test
mantel
group
number
death
record
day
week
pi
number
observ
death
compar
number
expect
death
mortal
would
ident
differ
group
null
hypothesi
one
group
rel
death
rate
ratio
number
observ
expect
death
differ
group
death
rate
compar
x
test
determin
statist
signific
differ
comparison
mean
viral
titer
determin
liver
brain
infect
mice
csatreat
untreat
group
perform
use
student
ttest
statist
analysi
neuropatholog
lesion
group
mice
determin
number
infect
brain
neuropatholog
lesion
one
lesion
usual
observ
infect
ie
mening
hydrocephalu
vascul
two
associ
lesion
three
associ
lesion
neuropatholog
lesion
rank
unrespeet
intens
lesion
comparison
differ
group
mice
perform
use
x
test
ietermin
statist
signific
observ
differ
csa
blood
level
repeatedli
test
group
infect
anim
end
llth
week
treatment
csa
blood
level
vari
ngml
mean
sd
ngml
consist
adequ
immunosuppress
effect
intraperiton
infect
induc
acut
hepat
danng
first
day
pi
lead
death
small
percentag
mice
fig
comparison
death
rate
x
test
group
ia
ib
ic
ic
id
statist
signific
p
csa
treatment
start
time
infect
given
daili
week
global
percentag
death
increas
fig
death
occur
acut
phase
infect
day
pi
tabl
group
ib
along
chronic
cn
infect
phase
week
pi
tabl
group
ib
control
group
uninfect
csatreat
mice
rate
death
occur
respect
day
pi
fig
tabl
group
nib
csa
treatment
start
week
pi
ie
acut
phase
infect
percentag
death
becam
respect
tabl
group
ic
ic
compar
late
death
infect
untreat
mice
tabl
group
ia
reach
statist
signific
csa
treatment
given
week
none
test
anim
die
even
treatment
start
time
infect
effect
csa
treatment
viral
titer
liver
brain
mice
determin
viral
titer
liver
brain
nine
csatreat
ten
untreat
mice
day
pi
time
viral
replic
reach
highest
level
previous
describ
tardieu
mean
viral
titer
liver
brain
obtain
three
differ
experi
moder
significantli
p
higher
csatreat
mice
compar
control
mice
tabl
viral
titer
determin
everi
day
first
week
pi
four
csatreat
four
untreat
mice
untreat
mice
viral
titer
liver
brain
increas
first
day
pi
reach
highest
level
day
pi
progress
decreas
low
valu
pfug
day
pi
confirm
previous
describ
result
tardieu
csatreat
mice
kinet
viral
titer
follow
curv
untreat
mice
highest
titer
obtain
day
pi
moder
higher
data
shown
test
week
pi
viral
titer
brain
liver
untreat
csatreat
infect
mice
similar
ie
reach
detect
level
pfug
tissu
group
mice
similar
individu
test
serum
sampl
eight
untreat
eight
csatreat
mice
even
csa
treatment
start
day
infect
interferon
titer
iuml
c
effect
csa
treatment
antibodi
titer
infect
mice
pool
three
sera
well
two
individu
test
sera
anim
antibodi
rose
first
week
pi
reach
titer
vari
judg
elisa
techniqu
titer
persist
week
pi
neutral
antibodi
present
sera
titer
five
differ
sera
infect
csatreat
mice
similarli
test
elisa
week
pi
ident
antibodi
titer
observ
true
sera
three
mice
whose
csa
treatment
begun
day
infect
neuropatholog
studi
perform
chronic
infect
mice
sacrif
week
pi
br
ns
spontan
dead
anim
remov
death
nenropatholog
observ
obtain
week
pi
similar
therefor
result
pool
csa
markedli
decreas
neuropatholog
consequ
chronic
cn
infect
shovm
fig
effect
observ
three
type
lesion
mening
hydrocephalu
vascuf
csa
treatment
begun
time
inocul
inject
dalli
end
experi
tabl
group
ib
mice
express
three
typic
neuropatholog
lesion
compar
oliv
oil
treatment
group
tabl
group
ia
differ
statist
signific
p
effect
csa
observ
even
treatment
begun
day
inocula
tabl
group
ic
mice
express
three
lesion
p
disappear
treatment
begun
later
tabl
group
ic
mice
express
three
lesion
p
shorter
period
time
tabl
group
iod
mice
express
three
lesion
p
csa
treatment
decreas
significantli
number
mice
complet
free
neuropatholog
lesion
shown
tabl
even
group
ib
last
column
mice
still
express
one
type
neuropatholog
lesion
usual
less
intens
degre
grade
observ
csauntreat
group
ia
csatreat
group
id
grade
csa
start
week
pi
group
ic
instead
week
pi
group
ic
hydrocephalu
observ
three
six
mice
intermedi
degre
intens
although
mening
vascul
observ
four
six
ndce
remain
low
degre
intens
twelv
anim
die
spontan
brain
obtain
death
neuropatholog
studi
two
anim
belong
csauntreat
oup
group
ia
mening
hydrocephalu
vascul
intens
judg
neuropatholog
studi
week
pi
death
perform
two
independ
examin
record
neuropatholog
lesion
wel
hydrocephalu
mening
vascul
lesion
analyz
coron
serial
section
later
hemispher
brain
stem
level
neuropathologicai
lesion
count
unrespect
intens
lesion
b
comparison
number
mice
express
three
type
lesion
hydrocephalu
mening
vascul
x
group
ia
ib
ic
statisti
signific
p
p
respect
nine
anim
belong
csatreat
group
ib
ic
lesion
seven
mice
slight
degre
mening
vascul
without
hydrocephalu
observ
one
mous
belong
csatreat
group
ic
intens
hydrocephalu
found
without
vascul
slight
degre
mening
cyclosporin
appear
modifi
acut
viral
diseas
consequ
chronic
cn
infect
induc
neurotrop
viru
acut
phase
infect
viral
titer
liver
brain
csatreat
mice
higher
observ
untreat
infect
mice
percentag
acut
death
among
csatreat
infect
mice
differ
although
statist
signific
dramat
experiment
model
test
csa
effect
acut
viral
diseas
thu
balbc
mice
infect
herp
viru
type
acut
mortal
increas
control
infect
anim
csatreat
mice
armend
b
similar
increas
acut
mortal
csa
treatment
observ
mice
suffer
myocard
coxsacki
infect
oconnel
interstiti
pneumonia
vesicular
stomat
viru
infect
charan
hand
csa
treatment
modifi
acut
mortal
andor
viru
titer
organ
mice
infect
either
influenza
schiltlmecht
mous
cytomegaloviru
gui
lymphochoriomening
viru
lolig
gather
differ
experiment
data
variat
effect
csa
acut
viral
infect
might
depend
upon
mechan
virusinduc
lesion
csa
appear
decreas
lesion
induc
acut
postvir
immun
respons
lolig
increas
acut
cytopathogeni
lesion
due
viral
replic
chaaran
oconnel
b
dose
csa
use
csa
titer
blood
howev
usual
avail
previou
experiment
report
c
time
csa
treatment
death
rate
increas
significantli
csa
treatment
start
time
viru
inject
observ
present
report
differ
factor
care
analyz
evalu
benefit
risk
csa
treatment
human
inflammatori
diseas
potenti
induc
viral
infect
model
increas
viral
replic
csatreat
anim
depend
decreas
product
ainterferon
sinc
ainterferon
titer
similar
blood
csatreat
control
infect
mice
result
agreement
previou
report
armend
b
gui
might
depend
effect
csa
either
postvir
cytotox
activ
essenti
mediat
cell
nk
cell
armend
b
chaaran
directli
viral
interact
cn
cell
gui
chronic
phase
infect
mortal
increas
significantli
among
anim
receiv
longterm
csa
treatment
start
day
viru
inocul
vs
infect
untreat
group
brain
anim
die
chronic
phase
none
three
neuropathologi
lesion
observ
viral
titer
brain
unmodifi
compar
control
infect
mice
circul
antibodi
titer
hand
longterm
csa
oliv
oil
treatment
uninfect
anim
induc
mortal
rate
respect
thu
increas
mortal
rate
among
csatreat
infect
mice
appear
depend
differ
addit
factor
ie
chronic
viral
infect
chronic
treatment
oliv
oil
alon
mix
csa
neuropatholog
consequ
infect
mening
hydrocephalu
vascul
absent
csatreat
mice
compar
untreat
mice
chronic
cn
infect
induc
mening
later
appear
vascul
reflect
intracerebr
hyperimmun
respons
induc
viral
inocul
postvir
immun
respons
part
cell
control
judg
suppress
cyclophosphamid
tardieu
csa
present
report
physiopatholog
mechan
lead
develop
hydrocephalu
still
unclear
high
affin
ependym
cell
tardieu
suggest
potenti
direct
effect
viru
ependym
cell
moreov
cyelophosphamid
spite
inhibitori
effect
mening
effect
hydrocephalu
tardieu
suggest
mening
main
caus
hydrocephalu
efficac
csa
suppress
hydrocephalu
develop
mice
particularli
strike
csa
treatment
start
time
viru
inject
suggest
ependym
particip
hydrocephalu
format
may
depend
induct
direct
effect
viru
ependym
cell
also
earli
cytotox
immun
respons
virusinfect
cell
outsid
cn
previou
report
show
csa
treatment
reduc
chronic
inflamm
lung
induc
influenza
viru
concomit
alter
delayedtyp
hypersensit
viru
schiltknecht
cn
effect
csa
chronic
immun
respons
suggest
inhibitori
effect
csa
express
experiment
allerg
enceph
eae
armend
b
inhibitori
effect
csa
inflamm
demyelin
spinal
cord
mice
persist
infect
theiler
murin
encephalomyel
viru
rodriguez
last
experiment
model
decreas
demyelin
correl
decreas
prolifer
lymphocyt
viru
myefin
antigen
final
csa
inject
start
day
pi
ie
acut
phase
viral
diseas
effect
treatment
preserv
csa
treatment
begun
week
pi
ie
inflamm
alreadi
establish
intens
mening
vascul
decreas
abolish
wherea
hydrocephalu
slightli
modifi
similar
result
import
timirg
start
csa
treatment
observ
theiler
viru
infect
model
rodriguez
preserv
csa
effici
intracn
inflammatori
lesion
maintain
low
risk
morbid
mortal
due
viral
replic
best
time
initi
treatment
seem
earli
po
tinfect
period
model
end
week
postinfect
import
clinic
use
csa
postvir
inflammatori
diseas
may
implic
toward
treatment
human
postinfecti
enceph
